منابع مشابه
Reboxetine – a ‘NaRI’ Clarify desipramine
Where is its place in therapy? ! There is no convincing evidence to suggest an overall advantage in efficacy, relapse prevention or speed of onset with reboxetine over existing antidepressants. ! It may be useful in SSRI resistant depression. More evidence is needed to support its use in indications such as anxiety, OCD and panic disorder. ! Noradrenergic deficiency differs to serotonergic defi...
متن کامل[Reboxetine in the treatment of bulimia nervosa].
There is a substancial body of literature demonstrating the efficacy of selective serotonin reuptake inhibitors antidepressants (SSRI) in reducing binge eating and vomiting frequency in Bulimia Nervosa. Good therapeutic response to noradrenergic agents, like desipramine and reboxetine, though not frequently reported in literature, has already been demonstrated. This case report describes the tr...
متن کاملBleeding and asymptomatic overdose in patients under Vitamin K antagonist therapy: Frequency and risk factors
Background Vitamin K antagonists are widely used in the treatment and prevention of thromboembolic disease. However, these drugs can cause serious side effects, especially bleeding. This study aims to evaluate frequency and risk factors of both bleeding and asymptomatic overdose in North African patients undergoing Vitamin K antagonist therapy. Methods We performed a cross-sectional study in ...
متن کاملThe promises and pitfalls of reboxetine.
The antidepressant compound, morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-,methanesulfonate, or reboxetine, is a selective noradrenergic reuptake inhibitor that acts by binding to the norepinephrine (NE) transporter and blocking reuptake of extracellular NE back into terminals. This compound has low affinity for other transporters and receptors. The development of reboxetine as a potential ant...
متن کاملMonotherapy with reboxetine in amphetamine withdrawal syndrome.
Amphetamine withdrawal can induce a condition with the symptoms of major depression. We report the case of a 46-year-old woman with antecedents of abuse of amphetamines and amphetamine derivatives from age 16 to age 41, who in the 5 years since withdrawal presented recurrent depression resistant to treatment. She was treated with maximum doses of selective serotonin reuptake inhibitors and lith...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The International Journal of Neuropsychopharmacology
سال: 2005
ISSN: 1461-1457,1469-5111
DOI: 10.1017/s1461145705005614